Frontiers in Immunology (Oct 2024)
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance
- Annalena Branz,
- Annalena Branz,
- Annalena Branz,
- Annalena Branz,
- Christian Matek,
- Christian Matek,
- Christian Matek,
- Christian Matek,
- Fabienne Lange,
- Fabienne Lange,
- Fabienne Lange,
- Fabienne Lange,
- Veronika Bahlinger,
- Veronika Bahlinger,
- Veronika Bahlinger,
- Veronika Bahlinger,
- Veronika Bahlinger,
- Niklas Klümper,
- Niklas Klümper,
- Niklas Klümper,
- Michael Hölzel,
- Michael Hölzel,
- Pamela L. Strissel,
- Pamela L. Strissel,
- Pamela L. Strissel,
- Pamela L. Strissel,
- Pamela L. Strissel,
- Reiner Strick,
- Reiner Strick,
- Reiner Strick,
- Reiner Strick,
- Danijel Sikic,
- Danijel Sikic,
- Danijel Sikic,
- Danijel Sikic,
- Sven Wach,
- Sven Wach,
- Sven Wach,
- Sven Wach,
- Helge Taubert,
- Helge Taubert,
- Helge Taubert,
- Helge Taubert,
- Bernd Wullich,
- Bernd Wullich,
- Bernd Wullich,
- Bernd Wullich,
- Arndt Hartmann,
- Arndt Hartmann,
- Arndt Hartmann,
- Arndt Hartmann,
- Barbara Seliger,
- Barbara Seliger,
- Markus Eckstein,
- Markus Eckstein,
- Markus Eckstein,
- Markus Eckstein
Affiliations
- Annalena Branz
- Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)), Erlangen, Germany
- Annalena Branz
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Annalena Branz
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Annalena Branz
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Christian Matek
- Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)), Erlangen, Germany
- Christian Matek
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Christian Matek
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Christian Matek
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Fabienne Lange
- Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)), Erlangen, Germany
- Fabienne Lange
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Fabienne Lange
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Fabienne Lange
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Veronika Bahlinger
- Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)), Erlangen, Germany
- Veronika Bahlinger
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Veronika Bahlinger
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Veronika Bahlinger
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Veronika Bahlinger
- Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany
- Niklas Klümper
- Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany
- Niklas Klümper
- Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany
- Niklas Klümper
- Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany
- Michael Hölzel
- Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany
- Michael Hölzel
- Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany
- Pamela L. Strissel
- Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)), Erlangen, Germany
- Pamela L. Strissel
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Pamela L. Strissel
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Pamela L. Strissel
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Pamela L. Strissel
- Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
- Reiner Strick
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Reiner Strick
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Reiner Strick
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Reiner Strick
- Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
- Danijel Sikic
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Danijel Sikic
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Danijel Sikic
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Danijel Sikic
- 0Department of Urology and Pediatric Urology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
- Sven Wach
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Sven Wach
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Sven Wach
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Sven Wach
- 0Department of Urology and Pediatric Urology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
- Helge Taubert
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Helge Taubert
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Helge Taubert
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Helge Taubert
- 0Department of Urology and Pediatric Urology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
- Bernd Wullich
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Bernd Wullich
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Bernd Wullich
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Bernd Wullich
- 0Department of Urology and Pediatric Urology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
- Arndt Hartmann
- Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)), Erlangen, Germany
- Arndt Hartmann
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Arndt Hartmann
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Arndt Hartmann
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- Barbara Seliger
- 1Institute of Translational Immunology, Medical School Brandenburg, Brandenburg, Germany
- Barbara Seliger
- 2Medical Faculty, Martin Luther University Halle-Wittenberg, Halle, Germany
- Markus Eckstein
- Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)), Erlangen, Germany
- Markus Eckstein
- CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- Markus Eckstein
- CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), Erlangen, Germany
- Markus Eckstein
- BZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- DOI
- https://doi.org/10.3389/fimmu.2024.1478196
- Journal volume & issue
-
Vol. 15
Abstract
IntroductionUrothelial bladder cancer is frequent and exhibits diverse prognoses influenced by molecular subtypes, urothelial subtype histology, and immune microenvironments. HLA-G, known for immune regulation, displays significant membranous expression in tumor tissues.MethodsWe studied the protein expression of Human Leucocyte Antigen G (HLA-G) in 241 Muscle-Invasive Bladder Cancer (MIBC) patients, elucidating its potential clinical and biological significance. Protein expression levels were evaluated and correlated with molecular subtypes, histological characteristics, immune microenvironment markers, and survival outcomes.ResultsHigh HLA-G expression associates with poor overall survival (OS) and diseasespecific survival (DSS), independent of clinicopathological parameters. HLA-G expression varies among molecular subtypes and Urothelial Subtype Histology, e.g., elevated expression levels in basal/squamous MIBC and those with sarcomatoid differentiation. Notably, HLA-G is increased in MIBC with an immune evasive microenvironment (high PD-L1 tumor cell expression, NK cell depletion, granzyme B (GZMB)/CD8 ratio reduction, MHC class I (MHCI) expression reduction) that are characterized by immunosuppressive features and poor prognosis. Furthermore, HLA-G correlates with elevated levels of other immune checkpoint proteins (TIGIT, LAG3, CTLA-4), indicating its role in immune evasion.DiscussionOur findings underscore HLA-G’s role as a potential prognostic marker and interesting immunotherapeutic target in MIBC. Its impact on immune evasion mechanisms and broad expression, coupled with associations withpoor survival and distinct tumor phenotypes, positions HLA-G as a promising protein for further exploration in developing targeted immunotherapies for MIBC patients.
Keywords